Hydroxychloroquine tablets
Sponsors
Makerere University, Kunming Pharmaceuticals, Inc.
Conditions
Covid19Discoid Lupus Erythematosus
Phase 2
Hydroxychloroquine for Treatment of Non-Severe COVID-19
NCT04860284
Start: 2020-09-18End: 2021-12-01Updated: 2021-04-26
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
Not yet recruitingNCT07557927
Start: 2026-04-30End: 2028-09-30Target: 100Updated: 2026-04-30